<DOC>
	<DOCNO>NCT00450320</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , sirolimus , work different way stop growth tumor cell , either kill cell stop dividing . Sirolimus also may stop growth tumor cell block enzymes need cell growth block blood flow tumor . PURPOSE : This pilot study study sirolimus treat patient HIV-related Kaposi 's sarcoma .</brief_summary>
	<brief_title>Sirolimus Treating Patients With HIV-Related Kaposi 's Sarcoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety toxicity sirolimus patient HIV-related Kaposi 's sarcoma ( KS ) receive protease inhibitor ( PI ) -based nonnucleoside reverse transcriptase inhibitor ( NNRTI ) -based highly active antiretroviral treatment ( HAART ) regimens . - Estimate dose ( ) drug require achieve target trough sirolimus plasma concentration 5-10 ng/mL patient receive PI-based NNRTI-based HAART regimens . Secondary - Evaluate clinical response KS patient treat sirolimus . - Determine effect drug mTOR-dependent signal peripheral blood mononuclear cell ( PBMC ) KS tumor biopsy . - Determine serum cytokine profile pre- post-treatment drug . - Determine effect drug HIV KS-associated herpesvirus ( KSHV ) viral load . - Determine effect drug T-lymphocyte subset . OUTLINE : This multicenter study . Patients assign 1 3 treatment group . - Group 1 ( patient receive PI-based HAART regimen ritonavir ) : Patients receive oral sirolimus 0.0015 mg/kg/day daily day 1-28 6 course long KS stable disease continue respond treatment . Patients may receive 6 additional course provide meet criterion response absence disease progression unacceptable toxicity . Patients stable disease 6 course discontinue treatment . - Group 2 ( patient receive PI-based HAART regimen without ritonavir ) : Patients receive oral sirolimus 0.003 mg/kg/day group 1 . - Group 3 ( patient receive NNRTI-based HAART regimen ) : Patients receive oral sirolimus 0.05 mg/kg/day group 1 . Blood sample collect periodically analyze sirolimus level via LCMSMS . PROJECTED ACCRUAL : A total 10 patient accrue study .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Kaposi</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Biopsyproven Kaposi 's sarcoma ( KS ) involve 1 follow tissue : Skin Lymph nod Oral cavity Gastrointestinal tract and/or lung , disease meet follow criterion : Asymptomatic minimally symptomatic Require systemic cytotoxic therapy At least five measurable , previously nonirradiated , cutaneous lesion ( indicator lesion ) Three nonindicator cutaneous lesion ≥ 4 x 4 mm accessible 3mm punch biopsy Serologic documentation HIV infection ( i.e. , positive enzymelinked immunosorbent assay , positive western blot , federally approve licensed HIV test , detectable blood level HIV RNA ) CD4 count &gt; 50 cells/µL Serum HIV RNA level &lt; 400 copies/mL KS either stable progress 4 week prior study entry stable antiretroviral therapy ≥ 12 week PIbased NNRTIbased regimen ≥ 3 drug , intention change regimen within 8 week start study drug PATIENT CHARACTERISTICS : Karnofsky performance status 70100 % Life expectancy ≥ 3 month Hemoglobin ≥ 8.0 g/dL Absolute neutrophil count ≥ 1,000/mm³ Platelet count ≥ 75,000/mm³ Glomerular filtration rate &gt; 40 mL/min Total bilirubin ≤ 1.5 time upper limit normal ( ULN ) ( ≤ 3.5 mg/dL due indinavir therapy direct bilirubin normal ; limit due atazanavir therapy direct bilirubin normal ) AST ALT ≤ 2.5 time ULN Fasting triglyceride ≤ 400 mg/dL ( 4.5 mmol/L ) Total cholesterol ≤ 300 mg/dL ( 7.8 mmol/L ) Spot urine protein : creatinine ratio ≤ 0.5 and/or proteinuria ≤ 500 mg No prior concurrent malignancy except treat basal cell skin cancer carcinoma situ cervix No evidence infiltrate , cavitation , consolidation ( i.e. , due infection serious medical illness ) chest xray within past 3 month No know hypersensitivity sirolimus derivative macrolide antibiotic No New York Heart Association class IIIIV cardiac disease ( e.g. , myocardial infarction within past 6 month ) No concurrent severe and/or lifethreatening medical disease No acute know chronic liver disease ( e.g. , chronic active hepatitis cirrhosis ) Hepatitis C documentation minimal fibrosis liver biopsy allow No concurrent active opportunistic infection Not pregnant nursing Negative pregnancy test Fertile patient must use effective barriermethod contraception 3 month completion study therapy PRIOR CONCURRENT THERAPY : No prior sirolimus No acute treatment infection serious medical illness within past 14 day No anticancer therapy KS , include chemotherapy , radiotherapy , biological therapy within past 4 week ( 6 week nitrosoureas mitomycin C ) No local therapy KS indicator lesion within past 60 day , unless lesion progress since treatment No investigational therapy within past 4 week No major surgery within past 2 week No prior concurrent treatment agent medication , antiretroviral drug use treat HIV infection , would interfere metabolism excretion sirolimus , include , limited , follow : Antifungals ( e.g. , voriconazole , itraconazole , ketoconazole ) Antibiotics ( e.g. , erythromycin , telithromycin , clarithromycin , rifampin , rifabutin ) Cidofovir Cisapride Diltiazem Cyclosporine Grapefruit juice Hypericum perforatum ( St. John 's wort ) No concurrent anticancer therapy , include chemotherapy , biological therapy , radiotherapy No concurrent systemic corticosteroid treatment , replacement dose No concurrent investigational therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>AIDS-related Kaposi sarcoma</keyword>
	<keyword>recurrent Kaposi sarcoma</keyword>
</DOC>